RxDoctor Payments Data

Kathy Kurtz

Family · Williamsville, NYNPI 1578560397

Payments from drug & device makers

$4,391in general payments, 2019–2025

Across 258 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$963
  • Johnson & Johnson$947
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$534
  • Bristol Myers Squibb$283
  • Pfizer$266
  • Takeda Pharmaceuticals U.S.A., Inc.$243
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,391 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$1,311
Medicare patients
13
Services billed
13

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide38$24,312
CreonLipase/Protease/Amylase11$19,423
Mesalamine15$13,631
Mesalamine ErMesalamine16$6,291
Dexlansoprazole DrDexlansoprazole14$3,990
Balsalazide Disodium22$3,872
Esomeprazole Magnesium27$3,235
Pantoprazole Sodium125$2,218
Omeprazole117$2,053
Famotidine83$1,647
Ursodiol12$1,473
Colestipol Hcl19$1,449
Lactulose13$836
CholestyramineCholestyramine (With Sugar)13$803
Metoclopramide Hcl28$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$963$43,73449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →